Deficient IL-6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis.


Journal

Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 12 11 2018
accepted: 15 04 2019
entrez: 24 7 2019
pubmed: 25 7 2019
medline: 25 7 2019
Statut: epublish

Résumé

Mechanisms underlying alcohol-induced liver injury and its progression still remain incompletely understood. Animal models can only address some aspects of the pathophysiology that requires studies directly in humans, which are scarce. We assessed liver inflammatory and immune responses at early stages of alcoholic liver disease in a unique cohort of alcohol-dependent patients undergoing a highly standardized alcohol withdrawal program. In active drinkers, quantitative real-time polymerase chain reaction revealed alcohol-induced activation of tumor necrosis factor alpha, interleukin (IL)-1β, and nuclear factor kappa B in liver tissue already at early disease stages. Double immunofluorescence staining indicated that this proinflammatory response was restricted to activated, CD68-positive macrophages. In parallel, down-regulation of IL-6, inhibition of the signal transducer and activator of transcription 3 (Stat3) pathway, as well as blunted cyclin D expression in hepatocytes, reduced proliferation and favored hepatocyte apoptosis. In addition, immunofluorescence and quantitative real-time polymerase chain reaction of liver tissue showed that alcohol also activated the toll-like receptor (TLR) 7-interferon (IFN) axis in hepatocytes, which was confirmed in alcohol-stimulated primary human hepatocytes and precision-cut liver slices

Identifiants

pubmed: 31334440
doi: 10.1002/hep4.1364
pii: HEP41364
pmc: PMC6601428
doi:

Types de publication

Journal Article

Langues

eng

Pagination

867-882

Références

Alcohol Res Health. 2000;24(2):77-84
pubmed: 11199281
Hepatology. 2001 Jul;34(1):101-8
pubmed: 11431739
Oncogene. 2002 Jan 3;21(1):32-43
pubmed: 11791174
Alcohol Clin Exp Res. 2002 Jan;26(1):74-82
pubmed: 11821657
Trends Immunol. 2002 Aug;23(8):375-8
pubmed: 12133792
J Immunol. 2004 Mar 1;172(5):2731-8
pubmed: 14978070
J Hepatol. 2005 Oct;43(4):687-95
pubmed: 16098628
Cell Mol Immunol. 2004 Jun;1(3):205-11
pubmed: 16219169
Cell Death Differ. 2006 May;13(5):816-25
pubmed: 16410796
Hepatology. 2006 May;43(5):989-1000
pubmed: 16628628
Alcohol. 2007 Jun;41(4):271-80
pubmed: 17630087
Gastroenterology. 2008 Apr;134(4):1148-58
pubmed: 18395093
J Immunol. 2008 Sep 1;181(5):3049-56
pubmed: 18713975
Hepatology. 2008 Oct;48(4):1224-31
pubmed: 18792393
J Exp Med. 1991 Nov 1;174(5):1209-20
pubmed: 1940799
Alcohol Clin Exp Res. 2010 Apr;34(4):719-25
pubmed: 20102572
Eur J Clin Invest. 2010 Jul;40(7):575-84
pubmed: 20658750
Nat Protoc. 2010 Sep;5(9):1540-51
pubmed: 20725069
Gastroenterol Res Pract. 2010;2010:null
pubmed: 20827314
Hepatology. 2010 Dec;52(6):2137-47
pubmed: 20931558
Hepatology. 2011 Feb;53(2):649-60
pubmed: 21274885
Alcohol Clin Exp Res. 2011 May;35(5):787-93
pubmed: 21284667
Hepatology. 2011 Sep 2;54(3):846-56
pubmed: 21725996
J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:89-93
pubmed: 22320924
Biochem J. 2012 Oct 1;447(1):25-34
pubmed: 22765640
Dig Dis. 2012;30 Suppl 1:55-60
pubmed: 23075869
Clin Liver Dis. 2012 Nov;16(4):667-85
pubmed: 23101976
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3507-12
pubmed: 23401516
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16544-9
pubmed: 24052526
J Vis Exp. 2013 Sep 03;(79):null
pubmed: 24056912
Hepatology. 2014 Jul;60(1):237-49
pubmed: 24375615
Mediators Inflamm. 2013;2013:495156
pubmed: 24385684
Alcohol Clin Exp Res. 2015 Mar;39(3):424-33
pubmed: 25703252
J Hepatol. 2015 Apr;62(1 Suppl):S38-46
pubmed: 25920088
Hepatol Int. 2014 Sep;8 Suppl 2:439-46
pubmed: 26201323
J Hepatol. 2016 Apr;64(4):872-80
pubmed: 26682726
Sci Rep. 2016 Jun 09;6:27849
pubmed: 27279075
J Neuroinflammation. 2017 Jan 25;14(1):22
pubmed: 28118842
Gene Expr. 2017 Jul 7;17(3):173-186
pubmed: 28411363
PLoS One. 2017 May 4;12(5):e0176173
pubmed: 28472150
RSC Adv. 2016;6(102):100652-100663
pubmed: 28546859
Handb Exp Pharmacol. 2018;248:397-431
pubmed: 29236160
Biomolecules. 2018 Jan 13;8(1):
pubmed: 29342874
J Immunol. 2018 Apr 1;200(7):2291-2303
pubmed: 29445009

Auteurs

Peter Stärkel (P)

Department of Hepato-gastroenterology Cliniques Universitaires Saint-Luc Brussels Belgium.
Institute of Experimental and Clinical Research, Laboratory of Hepato-gastroenterology Université Catholique de Louvain Brussels Belgium.

Bernd Schnabl (B)

Department of Medicine University of California San Diego La Jolla CA.

Sophie Leclercq (S)

Institute of Neuroscience Université Catholique de Louvain Brussels Belgium.

Mina Komuta (M)

Department of Pathology Cliniques Universitaires Saint-Luc Brussels Belgium.

Ramon Bataller (R)

Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine University of Pittsburgh Medical Center, Pittsburgh Liver Research Center Pittsburgh PA.

Josepmaria Argemi (J)

Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine University of Pittsburgh Medical Center, Pittsburgh Liver Research Center Pittsburgh PA.

Elena Palma (E)

Institute of Hepatology Foundation for Liver Research London United Kingdom.
Faculty of Life Sciences & Medicine King's College London London United Kingdom.

Shilpa Chokshi (S)

Institute of Hepatology Foundation for Liver Research London United Kingdom.
Faculty of Life Sciences & Medicine King's College London London United Kingdom.

Claus Hellerbrand (C)

Institute of Biochemistry Friedrich-Alexander University Erlangen-Nürnberg Erlangen Germany.

Luca Maccioni (L)

Institute of Experimental and Clinical Research, Laboratory of Hepato-gastroenterology Université Catholique de Louvain Brussels Belgium.

Nicolas Lanthier (N)

Department of Hepato-gastroenterology Cliniques Universitaires Saint-Luc Brussels Belgium.
Institute of Experimental and Clinical Research, Laboratory of Hepato-gastroenterology Université Catholique de Louvain Brussels Belgium.

Isabelle Leclercq (I)

Institute of Experimental and Clinical Research, Laboratory of Hepato-gastroenterology Université Catholique de Louvain Brussels Belgium.

Classifications MeSH